Skip to content

Released May 29, 2025, before the open

10-K filed May 29, 2025, 59 days after period end · 0001764013-25-000092

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$106.45MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$110,637,000N/M
Free Cash Flowderived-$110,838,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Net Income-$106.45M-$75.32M-$59.43M-$47.17M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR